Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.60 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RRM1 | P23921 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16151876 | 0.87 | ALDH1A1 (0.62) | CTSDALDH1A1MAPTCYP1A2CYP2C9 | |
| SCHEMBL27026753 | 0.86 | NPC1 (0.60) | GPR27CLK1ALDH1A1NPC1RAB9A | |
| SCHEMBL21591115 | 0.86 | GPR27 (0.52) | GPR27CLK1ALDH1A1NPC1RAB9A | |
| SCHEMBL22444976 | 0.85 | PLK1 (0.53) | GPR27CLK1ALDH1A1NPC1RAB9A | |
| SCHEMBL28552806 | 0.83 | KMT2A (0.54) | CTSDALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL16987303 | 0.82 | GAA (0.64) | GPR27CLK1ALDH1A1NPC1RAB9A | |
| SCHEMBL21412050 | 0.81 | ALDH1A1 (0.55) | GPR27CLK1ALDH1A1NPC1RAB9A | |
| SCHEMBL22859169 | 0.81 | GPR27 (0.46) | GPR27CLK1ALDH1A1NPC1RAB9A | |
| SCHEMBL22324639 | 0.81 | KDM4E (0.55) | GPR27CLK1ALDH1A1NPC1RAB9A | |
| SCHEMBL4939202 | 0.81 | TP53 (0.66) | CTSDALDH1A1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | ARES TRADING S.A. (CH) | 2020-06-30 | — | — | US | disclosed |
| WO-2009094205-A2 | 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094205-A2 | 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20080214622-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | BROWN ALAN DANIEL | 2008-09-04 | — | — | US | disclosed |
| US-20080214622-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | BROWN ALAN DANIEL | 2008-09-04 | — | — | US | disclosed |
| US-20080214622-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | BROWN ALAN DANIEL | 2008-09-04 | — | — | US | disclosed |
| EP-1863484-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100588-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006100588-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214622-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, PRLHR, KISS1R | CTSD 2233/4885GPR27 158/4885CLK1 3589/4885 |
| US-10696690-B2 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | APP, BACE1, PSEN1 | CTSD 3208/4885GPR27 2743/4885CLK1 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.